Drug intelligence / Profile preview

cydiodine

Development stage: Phase 2
Lead developer: Beijing Humanwell Junwei Healthcare Technology Development
Modality: Small Molecules
Administration: Buccal

Overview

**Cydiodine** is a buccal iodine antiseptic product marketed in China as **华素片**. Its active component is molecular iodine, which is released in saliva and directly halogenates microbial proteins, producing broad local microbicidal activity. It is supplied as a buccal tablet for local oral and pharyngeal use and is approved for chronic pharyngitis, oral ulcers, chronic gingivitis, and periodontitis. ([drugs.dxy.cn](https://drugs.dxy.cn/pc/drug/pZRuYfbpLqI8A3f9O1xa3Qg?ky=%E8%A5%BF%E5%9C%B0%E7%A2%98%E5%90%AB%E7%89%87))

Brand names: 华素片
Other names: Cydiodine Buccal Tablets西地碘西地碘含片

Beyond the preview

Go deeper on cydiodine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cydiodine.